Articles tagged "Malignancy"

2022 American Transplant Congress
Ex Vivo Liver Resection and Autotransplantation – Should It Be Used More Frequently?
J. Weiner¹, A. Griesemer¹, A. Hemming², D. Levi³, T. Beduschi⁴, R. Matsumoto¹, A. Mathur¹, J. Emond¹, T. Kato¹
¹Columbia University Irving Medical Center, New York, NY, ²University of Iowa, Iowa City, IA, ³Atrium Health, Charlotte, NC, ⁴University of Florida, Gainesville, FL
*Purpose: Ex vivo liver resection expands the limits of resectability for advanced liver tumors but remains underutilized due to concerns about technical complexity and vascular…
2022 American Transplant Congress
Public Acceptance of Living Donor Liver Transplant for Colorectal Liver Metastases: A National Survey
E. Pope-Collins, M. Nickels, K. Dokus, J. Martens, E. Keller, R. Hernandez-Alejandro, B. Al-Judaibi
University of Rochester, Rochester, NY
*Purpose: Recent advancements in cancer treatment and post-transplant management have allowed for a wider population of living donor transplant candidates. We employed a national survey…
2022 American Transplant Congress
Liver Transplantation for Patients with Fibrolamellar Hepatocellular Carcinoma: A Comprehensive Multicenter Analysis to Support Future Decision Making
M. P. Claasen¹, T. Ivanics¹, W. G. Polak², J. N. IJzermans², G. Sapisochin¹
¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²HPB and Transplant Surgery, Erasmus MC, Rotterdam, Netherlands
*Purpose: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare tumour accounting for ~1% of all primary liver cancers. Due to its rarity, there is a shortage…
2022 American Transplant Congress
Everolimus in Liver Transplantation for Diffuse, Unresectable Neuroendocrine Tumor
J. M. Vanatta¹, R. A. Helmick², C. Eymard², N. Nezakatgoo², P. Horton², J. P. Kothadia², S. P. Nair², J. D. Eason²
¹Transplantation, University of Tennessee/Methodist University Hospital, Memphis, TN, ²Transplantation, University of Tennessee, Memphis, TN
*Purpose: Liver transplantation (LT) has emerged as a therapy in selected patients for neuroendocrine tumor (NET) by providing cytoreduction. Progression-free survival in NET has been…
2022 American Transplant Congress
Nivolumab After Sorafenib Failure in Liver Recipients with HCC Recurrence
J. Kwon
Surgery, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: Several treatments have recently been known for hepatocellcular carcinoma (HCC) who have failed to treat sorafenib. Immune checkpoint inhibitors have proven to be effective,…
2022 American Transplant Congress
Characterizing Outcomes of Patients with Colorectal Liver Metastases (CRLM) Undergoing Liver Transplantation (LT) Evaluation
E. Takoushian¹, E. Brandon¹, B. Samstein², K. Halazun²
¹Liver Transplantation, New York Presbyterian Weill Cornell, New York, NY, ²Weill Cornell Medical Center, New York, NY
*Purpose: LT is a novel therapy for patients with unresectable CRLM. 5 year survival using LT appears to be significantly better than systemic chemotherapy in…
2022 American Transplant Congress
Frequency of Cervical Cancer Screening in Solid Organ Transplant Recipients
C. Papastamelos¹, K. Dokus², M. Laryea³
¹Internal Medicine, University of Rochester Medical Center, Rochester, NY, ²Transplant Division, University of Rochester Medical Center, Rochester, NY, ³Gastroenterology, University of Rochester Medical Center, Rochester, NY
*Purpose: Human papillomavirus-related anogenital malignancies disproportionately affect solid organ transplant recipients (SOTR) compared to the general population. Proposed cervical Pap testing intervals for SOTR differ…
2022 American Transplant Congress
Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma: An Analysis of the European Liver Transplant Registry
M. P. Claasen¹, T. Ivanics², J. N. IJzermans¹, G. Sapisochin², W. Polak¹
¹HPB and Transplant Surgery, Erasmus MC, Rotterdam, Netherlands, ²Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: Little is known about combined hepatocellular-cholangiocarcinoma (cHCC-CCA) demographics and their long-term outcomes after liver transplantation (LT). By analysing data from the European Liver Transplant…
2022 American Transplant Congress
Degree of Pre-Liver Transplant Immune Dysfunction Correlates with Post-Transplant Cancer Recurrence
G. S. Prakash¹, G. G. Panayotova¹, S. Simonishvili¹, Y. Qin¹, L. Jin¹, T. Ayorinde¹, L. J. Minze², F. Paterno¹, L. Brown¹, A. Amin¹, D. Liu¹, R. Ghobrial², J. V. Guarrera¹, K. E. Lunsford¹
¹Rutgers New Jersey Medical School, Newark, NJ, ²Houston Methodist Hospital, Houston, TX
*Purpose: Despite stringent selection criteria for liver transplant (LT) in patients with liver-limited malignancy, post-transplant cancer recurrence remains problematic. We have previously identified a pre-LT…
2022 American Transplant Congress
Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report
R. Saranu¹, S. Nikiforow², V. Jo³, H. So², P. Stowe², S. Tripathi¹, F. Cardarelli⁴, A. Chandraker¹
¹Renal Division, Brigham and Women's Hospital, Boston, MA, ²Dana Farber Cancer Institute, Boston, MA, ³Pathology, Brigham and Women's Hospital, Boston, MA, ⁴Allovir, Cambridge, MA
*Purpose: Epstein-Barr virus (EBV)-associated leiomyosarcomas (EBV+LMS) are neoplasms rarely seen in solid organ transplant (SOT) recipients and currently lack effective treatment options. We present a…

1
2
3
…
20
Next Page »